Learn More
Invitrogen™ KMT2D Recombinant Rabbit Monoclonal Antibody (9H13L17)
Description
This antibody is predicted to react with Monkey, Cat, Mouse and Sheep. Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
Specifications
Specifications
| Antigen | KMT2D |
| Applications | Immunocytochemistry |
| Classification | Recombinant Monoclonal |
| Clone | 9H13L17 |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.09% sodium azide; pH 7.2 |
| Gene | KMT2D |
| Gene Accession No. | O14686 |
| Gene Alias | AAD10; ALL1-related protein; ALR; CAGL114; Histone-lysine N-methyltransferase 2D; histone-lysine N-methyltransferase MLL2; KABUK1; Kabuki make-up syndrome; Kabuki mental retardation syndrome; KMS; KMT2D; lysine (K)-specific methyltransferase 2D; lysine methyltransferase 2D; lysine N-methyltransferase 2D; MLL2; MLL4; myeloid/lymphoid or mixed-lineage leukemia 2; Myeloid/lymphoid or mixed-lineage leukemia protein 2; TNRC21; trinucleotide repeat containing 21 |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.